Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

TFMFly

From Wikipedia, the free encyclopedia
TFMFly
Clinical data
Other namesTFM-FLY; TFM-Fly; DOTFM-FLY
Drug classSerotonin receptor modulator; Serotonin 5-HT2A receptor agonist
Legal status
Legal status
Illegal in Latvia
Identifiers
  • 1-[4-(trifluoromethyl)-2,3,6,7-tetrahydrofuro[2,3-f][1]benzofuran-8-yl]propan-2-amine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC14H16F3NO2
Molar mass287.282 g·mol−1
3D model (JSmol)
  • CC(CC1=C2CCOC2=C(C3=C1OCC3)C(F)(F)F)N
  • InChI=1S/C14H16F3NO2/c1-7(18)6-10-8-2-4-20-13(8)11(14(15,16)17)9-3-5-19-12(9)10/h7H,2-6,18H2,1H3
  • Key:KMWGSFWAZUVTCM-UHFFFAOYSA-N
  (verify)

TFMFly, or TFM-FLY, also known as DOTFM-FLY, is a serotonin receptor modulator of the phenethylamine, amphetamine and DOx, and FLY families related to psychedelics like DOTFM and DOB-FLY.[1][2][3]

Pharmacology

[edit]

Pharmacodynamics

[edit]

It acts as a potent agonist at the 5HT2A serotonin receptor subtype, and is a chiral compound with the more active (R) enantiomer having a Ki of 0.12 nM at the human 5-HT2A receptor.[2] While the fully aromatic benzodifurans such as Bromo-DragonFLY generally have higher binding affinity than saturated compounds like 2C-B-FLY,[1] the saturated compounds have higher efficacy as agonists.[4]

Chemistry

[edit]

Synthesis

[edit]

The chemical synthesis of TFMFly has been described.[1]

Analogues

[edit]

Analogues of TFMFly include DOTFM, DOB-FLY, and 25TFM-NBOMe, among others.

History

[edit]

TFMFly was first reported by a team at Purdue University led by David E. Nichols in 2001.[1][3]

Society and culture

[edit]
[edit]

Latvia

[edit]

TFMFly is illegal in Latvia.[5]

See also

[edit]

References

[edit]
  1. 1 2 3 4 Chambers JJ, Kurrasch-Orbaugh DM, Parker MA, Nichols DE (March 2001). "Enantiospecific synthesis and pharmacological evaluation of a series of super-potent, conformationally restricted 5-HT(2A/2C) receptor agonists". J Med Chem. 44 (6): 1003–1010. doi:10.1021/jm000491y. PMID 11300881.
  2. 1 2 Parrish JC, Braden MR, Gundy E, Nichols DE (December 2005). "Differential phospholipase C activation by phenylalkylamine serotonin 5-HT 2A receptor agonists". Journal of Neurochemistry. 95 (6): 1575–1584. doi:10.1111/j.1471-4159.2005.03477.x. PMID 16277614. S2CID 24005602.
  3. 1 2 Braden MR (2007). Towards a biophysical understanding of hallucinogen action (Ph.D. thesis). Purdue University. ProQuest 304838368.
  4. Heim R. Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur. Entwicklung eines neuen Struktur-Wirkungskonzepts (Ph.D. thesis) (in German). Freien Universität Berlin.
  5. "Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem" [Regulations on Narcotic Drugs, Psychotropic Substances and Precursors Controlled in Latvia] (in Latvian). Ministry of Health of the Republic of Latvia. Archived from the original on 2016-02-02. Retrieved 2015-10-15.
[edit]